

Lung Cancer Prevention Study

Are you a former smoker who smoked at least 20 pack years
(packs per day x number of years smoked)?

If yes, you may be eligible to participate in a lung cancer prevention study at the Denver VA Medical Center: A Phase 1 Trial of Inhaled Iloprost for the Prevention of Lung Cancer in Former Smoker.

Our previous study of the drug iloprost (in pill form) showed an improvement in areas of smoking induced premalignant airway damage in former smokers¹, so we're now testing an inhaled version of the drug to see if a direct delivery method works just as well or better.

The study includes but is not limited to:

- A sputum (spit) sample from the lungs
- Using a nebulizer to inhale either a study drug (iloprost) or placebo (inactive substance) for 2 months
- A bronchoscopy (scope of the lungs) before and after using the inhaled iloprost or placebo
- Physical exams, lab work and other testing such as pulmonary function testing

Compensation will be provided for participation

Principal Investigators: York Miller, MD and Robert Keith, MD Staff Physicians COMIRB#: 14-1247 Approved: 06/04/2015

References: 1.Keith RL, Blatchford PJ, Kittelson J, Minna JD, Kelly K, Massion PP, et al. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res (Phila) 2011 ;4:793-802.

Version 11.10.15 COMIRB APPROVED 07-Dec-2015

Please contact the study coordinator listed below in order to learn more about this study:

303-724-1657

Brandi Bagwell, MA

brandi.bagwell@ucdenver.edu (email)

Clinical Research Coordinator, University of Colorado Cancer Center, Denver VA Medical Center